HCW Biologics Inc.
Fusion immunotherapeutics combining immune cell engineering with novel biological mechanisms for autoimmune and cancer treatment
- Sector
- Biotech
- Headquarters
- MIRAMAR, FL
- Founded
- 2018
- Latest Form D
- $1.5M, Oct 2026
- Total capital
- $21.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $21.1M
- 5 Form D · last Oct 2026
- 1 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 10
- 30 pending · first 2022
- Rank in peer group#167 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$1.5M
- Private capital raisedForm D · SEC · 4th filing$4M
- Private capital raisedForm D · SEC · 3rd filing$6.9M
- Private capital raisedForm D · SEC · 2nd filing$2.5M
- Private capital raisedForm D · SEC · 1st filing$6.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#167 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Hing C WongResearcherExecutive Officer, DirectorLinked by 3 patents
- Fred M. MiddletonDirectorNamed in SEC Form D filings
- Gary M. WinerDirectorNamed in SEC Form D filings
- Lee S. FlowerExecutive OfficerNamed in SEC Form D filings
- Lee C FlowersExecutive OfficerNamed in SEC Form D filings
- Lisa M. GilesDirectorNamed in SEC Form D filings
Show all 12 people
- Nicole M. ValdiviesoExecutive OfficerNamed in SEC Form D filings
- Peter C RhodeExecutive OfficerNamed in SEC Form D filings
- Peter C SunDirectorNamed in SEC Form D filings
- Rebecca C. ByamExecutive OfficerNamed in SEC Form D filings
- Rick S. GreeneDirectorNamed in SEC Form D filings
- Scott T. GarrettDirectorNamed in SEC Form D filings
What it has protected
USPTO · 10 granted of 40- PendingMulti-chain Chimeric Polypeptides And Uses ThereofUSPTOApplication 19304367
- PendingSingle-chain Chimeric Polypeptides And Uses ThereofUSPTOApplication 19304242
- GrantedMethods Of Activating Regulatory T CellsUSPTOUS 12,398,189
Show all 40 patent records
- Multi-chain Chimeric Polypeptides And Uses ThereofMay 14, 2026 · Application 19304367Pending
- Single-chain Chimeric Polypeptides And Uses ThereofFeb 19, 2026 · Application 19304242Pending
- Methods Of Activating Regulatory T CellsAug 26, 2025 · US 12,398,189Granted
- Methods Of Treating Aging-related DisordersJul 2, 2024 · US 12,024,545Granted
- Single-chain Chimeric Polypeptides And Uses ThereofJun 25, 2024 · US 12,018,071Granted
- Single-chain Chimeric Polypeptides And Uses ThereofMay 21, 2024 · US 11,987,619Granted
- Multi-chain Chimeric Polypeptides And Uses ThereofJan 30, 2024 · US 11,884,712Granted
- Multi-chain Chimeric Polypeptides And Uses ThereofAug 29, 2023 · US 11,738,052Granted
- Methods For Stimulating Proliferation Or Differentiation Of An Immune Cell With A Multi-chain Chimeric PolypeptideAug 22, 2023 · US 11,730,762Granted
- Methods Of Treating Aging-related DisordersJun 13, 2023 · US 11,672,826Granted
- Multi-chain Chimeric Polypeptides And Uses ThereofDec 6, 2022 · US 11,518,792Granted
- Single-chain Chimeric Polypeptides And Uses ThereofAug 2, 2022 · US 11,401,324Granted
- Multi-chain Chimeric Polypeptides And Use Thereof In The Treatment Of Liver DiseasesApplication 63330757Pending
- Methods Of Modulating Circadian Clock Gene ExpressionApplication 63330715Pending
- Methods Of Reducing NeuroinflammationApplication 63330639Pending
- Method Of Treating Pancreatic CancerApplication 63315820Pending
- Method Of Treating Pancreatic CancerApplication 63315840Pending
- Multi-chain Chimeric Polypeptides And Use Thereof In The Treatment Of Liver DiseasesApplication 63232140Pending
- Methods Of Treating Aging-related DisordersApplication PCTUS2021035285Pending
- ANTI-CD26 Proteins And Uses ThereofApplication PCTUS2021029920Pending
- Methods Of Activating Regulatory T CellsApplication PCTUS2021017620Pending
- Chimeric Polypeptides And Uses ThereofApplication PCTUS2026011052Pending
- Chimeric Polypeptides and Uses ThereofApplication 63830440Pending
- Chimeric Polypeptides and Uses ThereofApplication 63744809Pending
- Chromatography Resin And Uses ThereofApplication PCTUS2021017621Pending
- Methods Of Treating Age-related And Inflammatory DiseasesApplication PCTUS2021017714Pending
- Methods Of Treating Aging-related DisordersApplication 63118536Pending
- Multi-chain Chimeric Polypeptides And Uses ThereofApplication PCTUS2020038717Pending
- Methods Of Treating Aging-related DisordersApplication PCTUS2020035598Pending
- Methods Of Treating Aging-related DisordersApplication 63032933Pending
- ANTI-CD26 Proteins And Uses ThereofApplication 63017467Pending
- Methods Of Activating Regulatory T CellsApplication 62981944Pending
- Chromatography Resin And Uses ThereofApplication 62982002Pending
- Methods Of Treating Age-related And Inflammatory DiseasesApplication 62975141Pending
- Single-chain And Multi-chain Chimeric Polypeptides And Uses ThereofApplication PCTUS2019049158Pending
- Methods Of Treating Aging-related DisordersApplication PCTUS2019049142Pending
- Multi-chain Chimeric Polypeptides And Uses ThereofApplication PCTUS2019048881Pending
- Single-chain Chimeric Polypeptides And Uses ThereofApplication PCTUS2019048930Pending
- Single-chain Chimeric Polypeptides And Uses ThereofApplication 62881039Pending
- Multi-chain Chimeric Polypeptides And Uses ThereofApplication 62881088Pending
Related companies, and why
- Cerebral TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Lindy Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- NewcelX Ltd.Similar federal contract value in Biotech · null in contracts
- Onchilles Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- IHP THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Cytoagents, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .